International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease

Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program

Research output: Contribution to journalArticlepeer-review


Purpose: Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging. Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. Conclusion: This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.

Original languageEnglish (US)
Pages (from-to)895-904
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number3
StatePublished - Feb 2022


  • Alzheimer’s disease (AD)
  • Brain imaging
  • F-flortaucipir
  • Positron emission tomography (PET)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this